Skip to main content
. Author manuscript; available in PMC: 2016 Sep 1.
Published in final edited form as: Clin Gastroenterol Hepatol. 2015 Oct 14;14(3):355–e32. doi: 10.1016/j.cgh.2015.09.036

Figure 2.

Figure 2

(A) Summary of maximally adjusted HR for association between premorbid BMI and pancreatic cancer-related mortality, comparing patients in the highest category of BMI with the lowest category. The size of the box corresponds to the weight of the given study. (B) Summary of maximally adjusted HR for association between premorbid BMI and pancreatic cancer-related mortality, comparing overweight (BMI 25.0–29.9 kg/m2) and obese (BMI ≥30 kg/m2) patients with normal BMI patients. The size of the box corresponds to the weight of the given study. (C) Summary of maximally adjusted HR for evaluation of dose-response relationship between premorbid BMI and pancreatic cancer–related mortality. The estimate represents mortality increase per 1 kg/m2 increase in BMI. SE, standard error.